Worth reading
58In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
723.1
%Wording
Definitive
How definitive the wording is.Revised forecast
Fiscal year ending May 2026 · cumulative period for the second quarter (interim period)Previous forecast published 2025 年７月 18 日Net Sales3,085→3,330million
+8.0%
Operating profit74→94million
+27.4%
Ordinary income51→165million
+224.0%
Profit attributable to owners of the parent11→90million
+723.1%
Net income per share1.16→9.92yen and sen
+755.2%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
売上高は医療機関経営支援事業の国内卸販売事業が好調に推移したこと等により計画を上回った。営業利益は国内のコスト削減の進捗と海外で利益率の高いサービスの受注好調により計画を上回った。経常利益および親会社株主に帰属する中間純利益は、これらに加えて為替差益が増加したこと等により計画を大幅に上回った。
Previous-period results売上高 2,912百万円、営業利益 47百万円、経常利益 67百万円、親会社株主に帰属する中間純利益 △17百万円、１株当たり中間純利益 △1.89円
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | ¥3,085 million → ¥3,330 million（+8.0%） |
| Operating profit | ¥74 million → ¥94 million（+27.4%） |
| Ordinary income | ¥51 million → ¥165 million（+224.0%） |
| Profit attributable to owners of the parent | ¥11 million → ¥90 million（+723.1%） |
| Net income per share | 1.16 yen and sen → 9.92 yen and sen |
| Fiscal Period Covered | Fiscal year ending May 2026 |
| Period Covered | cumulative period for the second quarter (interim period) |
| Publication date of previous forecast | 2025 年７月 18 日 |
| Previous-period results | 売上高 2,912百万円、営業利益 47百万円、経常利益 67百万円、親会社株主に帰属する中間純利益 △17百万円、１株当たり中間純利益 △1.89円 |
| Reason for the revision | 売上高は医療機関経営支援事業の国内卸販売事業が好調に推移したこと等により計画を上回った。営業利益は国内のコスト削減の進捗と海外で利益率の高いサービスの受注好調により計画を上回った。経常利益および親会社株主に帰属する中間純利益は、これらに加えて為替差益が増加したこと等により計画を大幅に上回った。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.医療機関経営支援事業の国内卸販売事業が好調に推移したこと、国内でのコスト削減が進捗したこと、海外で利益率の高いサービスの受注が好調だったことに加え、円安による為替差益が増加したこと。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.